Dr. Joanna Mitri, the company’s chief medical officer, shared the update in a Product Theater session at the ADA Scientific Sessions in Chicago today. Mitri said the company plans to launch the automated insulin delivery system on July 7. The company had said as recently as March that it previously expected a second-quarter launch.
Sequel built its twiist system on underlying drug delivery technology developed by DEKA R&D. Dean Kamen, co-founder of Sequel and founder of DEKA, commercialized the first wearable insulin pump for diabetes and last year said the twiist system “represents the next generation of insulin delivery.” Sequel won FDA clearance for the twiist system in March 2024.
Combined with the twiist Loop algorithm, the pump directly measures the volume of insulin delivered with every microdose. It offers the capability and flexibility to address each patient’s individual dosing needs. Sequel’s system utilizes sound waves that measure each pulse of insulin. This enables precision and helps understand exactly how much insulin the patient receives in a dose.
twiist features iiSure technology, which includes four checkpoints to provide accurate delivery and alert users to blockages quickly. Cleared for ages six and up with type 1 diabetes, the system offers a personalized way to manage the condition.
Sequel announced in March that it agreed with Abbott to make the Libre system its first continuous glucose monitor (CGM) integration for twiist. The company also recently struck an agreement with Abbott to integrate with a future dual glucose-ketone sensor and has a deal to integrate the pump with the Senseonics Eversense 365 year-long implantable CGM.
